Infectious Diseases

Provides guidance on vaccine dosage schedules and interchangeability, as well as vaccine use in special populations.

Third drug to be filed for treatment of COVID-19 under Interim Order, following IV remdesivir and IV bamlanivimab.

NACI issues recommendations for use in special populations and addresses other key issues including vaccine efficacy, co-administration with other vaccines, dosing, post-vaccination counselling.

Health Canada advises patients to tell healthcare providers about any history of serious allergic reactions before receiving COVID-19 vaccine.

Canadian Immunization Guide updates chapter on assessment and initial management of acute adverse reactions in vaccine recipients.

Shoulder injury caused by injecting too high into the shoulder can be prevented with proper injection technique.

WHO finds insufficient evidence that remdesivir improves survival or other outcomes in hospitalized patients with COVID-19, regardless of disease severity.